AMH – Ovarreserve nach onkologischen Erkrankungen
Tóm tắt
Từ khóa
Tài liệu tham khảo
Zentrum für Krebsregisterdaten im Robert Koch-Institut: Datenbankabfrage mit Schätzung der Inzidenz, Prävalenz und des Überlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten (DOI: 10.18444/5.03.01.0005.0014.0001). Mortalitätsdaten bereitgestellt vom Statistischen Bundesamt. www.krebsdaten.de/abfrage, Letzte Aktualisierung: 17.12.2019, Abrufdatum: (25. Mai 2020)
https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Kurzbeitraege/Archiv2018/2018_4_Thema_des_Monats_lebensverlauf.html. Zugegriffen: 11.09.2020
Bruning P, Pit M, de Jong-Bakker M et al (1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308–310. https://doi.org/10.1038/bjc.1990.58
Jeanes H, Newby D, Gray GA (2007) Cardiovascular risk in women: the impact of hormone replacement therapy and prospects for new therapeutic approaches. Expert Opin Pharmacother 8(3):279–288. https://doi.org/10.1517/14656566.8.3.279
Zemlin C, Herrmann-Lingen C, Wiegard K, Kleiber C, Kolb-Niemann B, Lubbe D, Schade-Brittinger C, Wagner U, Albert U‑S (2011) Implementierung eines EDV- und Screening-gestützten psychoonkologischen Versorgungspfads
Green DM, Sklar CA, Boice JD Jr et al (2009) Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 27(14):2374–2381. https://doi.org/10.1200/JCO.2008.21.1839
Lawrenz B, Jauckus J, Kupka MS, Strowitzki T, von Wolff M (2011) Fertility preservation in 〉1,000 patients: patient’s characteristics, spectrum, efficacy and risks of applied preservation techniques. Arch Gynecol Obstet 283(3):651–656. https://doi.org/10.1007/s00404-010-1772-y
Dittrich R, Kliesch S, Schüring A et al (2018) Fertility preservation for patients with malignant disease. Guideline of the DGGG, DGU and DGRM (S2k-level, AWMF registry no. 015/082, november 2017)—recommendations and statements for girls and women. Geburtshilfe Frauenheilkd 78(6):567–584. https://doi.org/10.1055/a-0611-5549
Fleming R, Seifer DB, Frattarelli JL, Ruman J (2015) Assessing ovarian response: antral follicle count versus anti-Müllerian hormone. Reprod Biomed Online 31:486–496. https://doi.org/10.1016/j.rbmo.2015.06.015
Dumont A, Robin G, Catteau-Jonard S, Dewailly D (2015) Role of anti-Müllerian hormone in pathophysiology, diagnosis and treatment of polycystic ovary syndrome: a review. Reprod Biol Endocrinol 13:137. https://doi.org/10.1186/s12958-015-0134-9
Kuiri-Hanninen T, Kallio S, Seuri R, Tyrvainen E, Liakka A, Tapanainen J et al (2011) Postnatal developmental changes in the pituitary-ovarian axis in preterm and term infant girls. J Clin Endocrinol Metab 96(11):3432–3439. https://doi.org/10.1210/jc.2011-1502
van Rooij IA, Broekmans FJ, te Velde ER et al (2002) Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 17(12):3065–3071. https://doi.org/10.1093/humrep/17.12.3065
Crofton PM, Illingworth PJ, Groome NP, Stirling HF, Swanston I, Gow S, Wu FCW, McNeilly A, Kelnar CJH (1997) Changes in dimeric inhibin A and B during normal early puberty in boys and girls. Clin Endocrinol 46:109–114. https://doi.org/10.1046/j.1365-2265.1997.d01-1744.x
Brougham MF, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WH (2012) Anti-Müllerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab 97(6):2059–2067. https://doi.org/10.1210/jc.2011-3180
La Marca A, Malmusi S, Giulini S et al (2004) Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19(12):2738–2741. https://doi.org/10.1093/humrep/deh508
Tran ND, Cedars MI, Rosen MP (2011) The role of anti-müllerian hormone (AMH) in assessing ovarian reserve. J Clin Endocrinol Metab 96(12):3609–3614. https://doi.org/10.1210/jc.2011-0368
Durlinger AL, Gruijters MJ, Kramer P et al (2002) Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 143(3):1076–1084. https://doi.org/10.1210/endo.143.3.8691
Visser JA, Themmen AP (2005) Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol 234(1–2):81–86. https://doi.org/10.1016/j.mce.2004.09.008
van Helden J, Weiskirchen R (2015) Performance of the two new fully automated anti-Müllerian hormone immunoassays compared with the clinical standard assay. Hum Reprod 30(8):1918–1926. https://doi.org/10.1093/humrep/dev127
Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA (2003) Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 18(11):2368–2374. https://doi.org/10.1093/humrep/deg473
Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D (2010) Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online 20(2):280–285. https://doi.org/10.1016/j.rbmo.2009.11.010
Kim HA, Choi J, Park CS et al (2018) Post-chemotherapy serum anti-Müllerian hormone level predicts ovarian function recovery. Endocr Connect 7(8):949–956. https://doi.org/10.1530/EC-18-0180
Anderson RA, Rosendahl M, Kelsey TW, Cameron DA (2013) Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer 49(16):3404–3411. https://doi.org/10.1016/j.ejca .2013.07.014
Jayasinghe YL, Wallace WHB, Anderson RA (2018) Ovarian function, fertility and reproductive lifespan in cancer patients. Expert Rev Endocrinol Metab 13(3):125–136. https://doi.org/10.1080/17446651.2018.1455498
Su HC, Haunschild C, Chung K et al (2014) Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer 120(23):3691–3698. https://doi.org/10.1002/cncr.28942
Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF (2017) The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 87:58–64. https://doi.org/10.1016/j.ejca .2017.10.001 t
van Dorp W, Mulder RL, Kremer LC et al (2016) Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the pancareSurFup consortium. J Clin Oncol 34(28):3440–3450. https://doi.org/10.1200/JCO.2015.64.3288
Anderson RA, Remedios R, Kirkwood AA et al (2018) Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin’s lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. Lancet Oncol 19(10):1328–1337. https://doi.org/10.1016/S1470-2045(18)30500-X
Fertilitätserhalt bei onkologischen Erkrankungen. Leitlinie der DGGG, DGU, DGRM (S2k-Level, AWMF-Registernummer 015/082, September 2017) – Empfehlungen und Statements bei Mädchen und Frauen, Georg Thieme Verlag KG Stuttgart · New York
Wallace WH, Thomson AB, Kelsey TW (2003) The radiosensitivity of the human oocyte. Hum Reprod 18(1):117–121. https://doi.org/10.1093/humrep/deg016
Wallace WH, Thomson AB, Saran F, Kelsey TW (2005) Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 62(3):738–744. https://doi.org/10.1016/j.ijrobp.2004.11.038
Wong QHY, Anderson RA (2018) The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery. Curr Opin Endocrinol Diabetes Obes 25(6):391–398. https://doi.org/10.1097/MED.0000000000000447
Lie Fong S, Lugtenburg PJ, Schipper I, Themmen APN, de Jong FH, Sonneveld P, Laven JSE (2008) Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reproduction 23(3):674–678. https://doi.org/10.1093/humrep/dem392
Evranos B, Faki S, Polat SB, Bestepe N, Ersoy R, Cakir B (2018) Effects of radioactive iodine therapy on ovarian reserve: a prospective pilot study. Thyroid 28(12):1702–1707. https://doi.org/10.1089/thy.2018.0129
Loren AW, Mangu PB, Beck LN et al (2013) Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(19):2500–2510. https://doi.org/10.1200/JCO.2013.49.2678
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125085s225lbl.pdf revised 2011. Zugegriffen: 11.09.2020
Lawrenz B et al (2012) Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma—evaluation by using antimüllerian hormone and retrieved oocytes. Fertil Steril 98(1):141–144
Gaiolla RD, Domingues MA, Niéro-Melo L, de Oliveira DE (2011) Serum levels of interleukins 6, 10, and 13 before and after treatment of classic Hodgkin lymphoma. Arch Pathol Lab Med 135(4):483–489. https://doi.org/10.1043/2010-0060-OA.1
Huober-Zeeb C, Lawrenz B, Popovici RM et al (2011) Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. Fertil Steril 95(1):342–344. https://doi.org/10.1016/j.fertnstert.2010.07.1074
https://www.ferring.de/assets/Uploads/FG004750-von-Wolff-Perspektive-Fertilitaet-Fertilitaetsprotektive-Massnahmen.pdf. Zugegriffen: 11.09.2020